Skip to main content

Adult EASI Efficacy Results

In the treatment of adults with uncontrolled moderate-to-severe atopic dermatitis

CLEARER SKIN AFTER FIRST DOSE AT WEEK 2, SUSTAINED AT 1 YEAR

Significant skin clearance in 3 pivotal trials1

CHRONOS
18+ YEARS
easi-75 AT
WEEKs 16 AND 52
(secondary endpoint)2,3,a-c

Definitive conclusions cannot be made at Week 2, as this was a post hoc analysis. Data were not multiplicity controlled and P value was nominal.

Significant improvement in lesion extent and severity was also demonstrated with DUPIXENT in monotherapy trials1,4

  • 51% of adults treated with DUPIXENT (n=224) achieved ≥75% improvement in lesion extent and severity (EASI-75; secondary endpoint) vs 15% with placebo at Week 16 in SOLO 1 (n=224; P<0.001)
  • 44% of adults treated with DUPIXENT (n=233) achieved ≥75% improvement in lesion extent and severity (EASI-75; secondary endpoint) vs 12% with placebo at Week 16 in SOLO 2 (n=236; P<0.001)

≥90% skin improvement at 1 year

CHRONOS 18+ years
EASI-90
(post hoc analysis)3,a-c

Definitive conclusions cannot be made for EASI-90 at Week 52, as this was a post hoc analysis in which data were not multiplicity controlled.

aIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.

bFull Analysis Set includes all subjects randomized.

cIn CHRONOS, as needed, subjects received topical calcineurin inhibitors for problem areas only, such as the face, neck, and intertriginous and genital areas.

dWeek 52 data were limited to patients completing 52 weeks as of the cutoff date.

Explore more severity index results

VIEW ADOLESCENT
(12 TO 17 YEARS) DATA VIEW INFANT TO PRESCHOOLER
(6 MONTHS TO 5 YEARS) DATA VIEW CHILD
(6 TO 11 YEARS) DATA VIEW AD PATIENTS (12+ years)
WITH HAND AND/OR FOOT
INVOLVEMENT DATA

Measuring the extent and severity of lesional signs of atopic dermatitis

EASI combines the severity of the signs of eczema and the extent of skin involvement.4

The severity of each of
4 eczema signs is
assessed on a scale of
0 to 34

The extent of lesions in each body region is evaluated based on the percentage of involvement and is given a value between 0 and 6. Each body region value is then weighted by a corresponding multiplier; lower extremities are weighted more while head and neck are weighted the least.4

Each region gets a total region score:

Severity Score x Area Score x Multiplier = Region Score

The final EASI score is the sum of all 4 region scores. The composite score, on a scale from 0 to 72, determines the severity of the signs of eczema and the extent to which the patient is affected.4,e

An improvement of at least 75% in lesion extent and severity (EASI-75) from baseline is a clinically meaningful change.1

eIn patients <8 years of age, the multipliers for the head and neck are 0.2, the trunk is 0.3, the upper extremities are 0.2, and the lower extremities are 0.3. In patients ≥8 years of age, the multipliers for the head and neck are 0.1, the trunk is 0.3, the upper extremities are 0.2, and the lower extremities are 0.4.4

READY TO PRESCRIBE DUPIXENT?

DOSAGE AND ADMINISTRATION